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Abstract
Background: Attention Deficit Hyperactivity Disorder, commonly referred to as ADHD, is a
common, complex, predominately genetic but highly treatable disorder, which in its more severe
form has such a profound effect on brain function that every aspect of the life of an affected
individual may be permanently compromised. Despite the broad base of scientific investigation over
the past 50 years supporting this statement, there are still many misconceptions about ADHD.
These include believing the disorder does not exist, that all children have symptoms of ADHD, that
if it does exist it is grossly over-diagnosed and over-treated, and that the treatment is dangerous
and leads to a propensity to drug addiction. Since most misconceptions contain elements of truth,
where does the reality lie?
Results: We have reviewed the literature to evaluate some of the claims and counter-claims. The
evidence suggests that ADHD is primarily a polygenic disorder involving at least 50 genes, including
those encoding enzymes of neurotransmitter metabolism, neurotransmitter transporters and
receptors. Because of its polygenic nature, ADHD is often accompanied by other behavioral
abnormalities. It is present in adults as well as children, but in itself it does not necessarily impair
function in adult life; associated disorders, however, may do so. A range of treatment options is
reviewed and the mechanisms responsible for the efficacy of standard drug treatments are
considered.
Conclusion: The genes so far implicated in ADHD account for only part of the total picture.
Identification of the remaining genes and characterization of their interactions is likely to establish
ADHD firmly as a biological disorder and to lead to better methods of diagnosis and treatment.
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Prevalence
ADHD is one of the most well-recognized childhood
developmental problems. This condition is characterized
by inattention, hyperactivity and impulsiveness. It is now
known that these symptoms continue as problems into
adulthood for 60% of children with ADHD. That trans-
lates into 4% of the US adult population, or 8 million
adults. However, few ADHD adults are identified or
treated. Adults with ADHD may have difficulty following
directions, remembering information, concentrating,
organizing tasks or completing work within time limits. If
these difficulties are not managed appropriately, they can
cause associated behavioral, emotional, social, vocational
and academic problems. ADHD afflicts 3% to 7.5% of
school-age children [1-4]. An estimated 30% to 70% of
those will maintain the disorder into adulthood. Preva-
lence rates for ADHD in adults are not as well determined
as rates for children, but fall in the 1% to 5% range.
ADHD affects males at higher rate than females in child-
hood, but this ratio seems to even out by adulthood.
Dispelling the myths
How is ADHD diagnosed?
The diagnosis of ADHD is based on criteria outlined by
the Diagnostic and Statistical Manual of the American
Psychiatric Association Version 4-TR [1]. This is referred to
as the DSM-IV-TR™. Table 1 illustrates these criteria. Sev-
eral similar criteria were set out in earlier versions of the
DSM. While the names have changed somewhat, all have
included the letters ADD in one form or another, repre-
senting the core of the disorder – Attention Deficit Disor-
der. The subtypes in the DMS-IV are ADHD-I,
Table 1: DSM-IV Diagnostic Criteria for Attention-Deficit/Hyperactivity Disorder
A. Either (1) or (2)
(1) six (or more) of the following symptoms of inattention have persisted for at least 6 months to a degree that is maladaptive and inconsistent 
with developmental level:
Inattention
(a) often fails to give close attention to details or makes careless mistakes in schoolwork, work, or other activities
(b) often has difficulty sustaining attention in tasks or play activities
(c) often does not seem to listen when spoken to directly
(d) often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace (not due to oppositional 
behavior or failure to understand instructions)
(e) often has difficulty organizing tasks and activities
(f) often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such as schoolwork or homework)
(g) often loses things necessary for tasks or activities (e.g., toys, school assignments, pencils, books, or tools)
(h) is often easily distracted by extraneous stimuli
(i) is often forgetful in daily activities
(2) six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at least 6 months to a degree that is maladaptive 
and inconsistent with developmental level:
Hyperactivity
(a) often fidgets with hands or feet or squirms in seat
(b) often leaves seat in classroom or in other situations in which remaining seated is expected
(c) often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, may be limited to subjective 
feelings of restlessness)
(d) often has difficulty playing or engaging in leisure activities quietly
(e) is often "on the go" or often acts as if "driven by a motor"
(f) often talks excessively
Impulsivity
(g) often blurts out answers before questions have been completed
(h) often has difficulty awaiting turn
(i) often interrupts or intrudes on others (e.g., butts into conversations or games)
B. Some hyperactivity-impulsive or inattentive symptoms that caused impairment were present before age 7 years
C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or work] and at home)
D. There must be clear evidence of clinically significant impairment in social, academic, or occupational functioning
E. The symptoms do not occur exclusively during the course of a Pervasive Developmental Disorder, Schizophrenia, or other Psychotic Disorder 
and are not better accounted for by other mental disorder (e.g., Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a Personality 
Disorder).
Code based on type:
314.01 Attention-Deficit/Hyperactivity Disorder, Combined Type: if both Criteria A1 and A2 are met for the past 6 months
314.00 Attention-Deficit/Hyperactivity Disorder, Predominately Inattentive Type: if Criterion A1 is met but Criterion A2 is not met 
for the past 6 months
314.01 Attention-Deficit/Hyperactivity Disorder, Predominately Hyperactive-Impulsive Type: if Criterion A2 is met but Criterion A1 
is not met for the past 6 monthsTheoretical Biology and Medical Modelling 2005, 2:50 http://www.tbiomed.com/content/2/1/50
Page 3 of 15
(page number not for citation purposes)
representing predominately the inattentive type, ADHD-
H, representing predominately the hyperactive-impulsive
type, and ADHD-C, representing the combined type.
ADHD is a common disorder
Estimates of the frequency of the various types of ADHD,
based on population surveys, have shown variable results.
The advantage of population based samples, in contrast to
clinic based samples, is that individuals in the community
who have not sought medical attention are included.
Table 2 shows the results of Wolraich et al. [3] for all three
subtypes of ADHD based on teacher reports for grades K
through 5 in a countywide sample of 4,323 children in
Tennessee. An epidemiological study of children and ado-
lescent twins in Missouri showed a frequency of all types
of ADHD of 3.5% in girls and 7.5% in boys [2]. In the
Wolraich et al study [3], only 11 to 33% of the cases had
received a diagnosis of ADHD and only 8 to 26% were
being treated with stimulant medication. A Centers for
Disease Control survey showed that in the year 2003 4.4
million children 4 to 17 years of age were reported to have
a diagnosis of ADHD. Of these, 56% were receiving med-
ications for the disorder [5]. These figures are contrary to
the notion that ADHD is over-diagnosed and over-treated.
While many of these children can be handled by appropri-
ate teaching methods and do not require treatment, the
figures suggest that ADHD-I, at least, is probably under-
diagnosed and under-treated.
Clinical aspects of ADHD
It is one thing to read a list of the symptoms in Table 1 and
quite another to experience the ADHD child at first hand,
as teachers and parents of affected children do. Individu-
als with ADHD tend to be disorganized. Children have
messy lockers and rooms and both children and adults
have cluttered desks. Their daily activities tend to be cha-
otic. They have trouble making plans and even more trou-
ble in carrying out plans in an orderly fashion. Because of
problems with attention and focus, they have trouble
completing what they start and leave tasks unfinished,
plans unrealized. Attics and basements are likely to be
filled with partly completed projects, repairs, and note-
books; desk drawers are likely to be cluttered with unfin-
ished letters, outlines and project plans. Although many
individuals with ADHD are highly intelligent, they tend to
be underachievers, a result of their poor concentration
and inability to sustain interest. They become bored easily
and have trouble entertaining themselves. Reading books
is very difficult. Family, friends, teachers and coworkers
often become impatient with them and expect them to
fail. Their life is so full of tumult that even a minor addi-
tional change in their routine can be upsetting.
Individuals with ADHD have a very low level of tolerance
to frustration and stress. This results in irritability and
poor anger control. The anger tends to come on suddenly
and explosively with slamming doors, punching holes in
walls, verbal abuse of those around them, tantrums, and
leaving important meetings in a frenzy. Children get into
fights, adults blow up and lose jobs and alienate friends.
Afterwards they are sorry, but the damage is done. Because
of their low tolerance for frustration they are very impa-
tient. They hate to wait in line, and delays of any kind
make them frantic. Whatever is going on – a trip, a movie,
a class, a discussion – they want it to go quickly and be fin-
ished. Because of their impulsivity both children and
adults may leap into action without thinking of conse-
quences. As adults, they drive too fast, use power tools
carelessly, and plunge into activities without thinking of
the danger. As children they often appear fearless, do dan-
gerous things, climb too high in trees, and may dart into
traffic without looking. The result is they often hurt them-
selves or others. People with ADHD have trouble with
their orientation to time and space. They may have to stop
and think which is their right hand and which is their left;
may have difficulty following a set of instructions, reading
a map or telling time. People often complain they can
never get to places on time. Because of their difficulty in
planning ahead, they leave too little time to get places. If
they live 30 minutes from the place of an appointment,
they often leave home at the time of the appointment,
making themselves 30 minutes late. It takes little imagina-
tion to realize that may of these traits make for difficult
interpersonal relationships and problems in school and
on the job. With adults a history of many failed marriages
and many job changes is common. This is a flavor of just
some of the issues that ADHD children and adults face.
ADHD is a genetic disorder
For many years, clinicians caring for children with ADHD
have noted that the condition is common in one or both
of the parents. While this suggests that ADHD may have a
strong genetic basis, environmental factors could cause
the same familiar pattern. Twin studies provide much
stronger evidence for the role of genetic factors. Several
large twin studies of ADHD have been completed in the
last 15 years. They show that the concordance rate in iden-
tical twins is usually greater than 65% while that in frater-
nal twins is usually less than 40%. This is consistent with
75 to 95% of ADHD being genetically caused, the remain-
Table 2: Prevalence of various types of ADHD in the general 
population
From Wolraich et al. (1998)
Hyperactive/Impulsive 2.6
Inattentive 8.8
Combined 4.7
Total 16.1
M/F ratio 4:1Theoretical Biology and Medical Modelling 2005, 2:50 http://www.tbiomed.com/content/2/1/50
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der being environmental [6-8]. One reason why twin
studies are valuable is that if a behavior or disorder was
primarily environmental, the effect should be comparable
whether the twins were identical for fraternal, since both
identical and fraternal twins usually live together for at
least the early part of their life. A significant drop in con-
cordance rate from identical to fraternal twins suggests
genetic but not environmental factors.
The environmental portion can be divided into a shared
and unshared component. The shared component refers
to exposure to the same environment while the unshared
portion refers to exposure to different environments. The
former is more likely to occur early in childhood, while
the latter is more likely to occur later in childhood. The
early shared environment is the part of life that Freud and
many other psychiatrists and psychologists assumed was
the most formative part of a child's life in terms of their
adult behavior. An additional part of the twin studies of
great interest was that the shared environment was usually
found to contribute to essentially 0% of the environmen-
tal component [6]. Most of the environmental compo-
nent was due to unshared experiences later in life.
A number of adoption studies of ADHD have also been
reported [9-11]. These are particularly valuable in separat-
ing genetic from environmental factors. If a child is
adopted at birth, there is no opportunity for the biological
parent to influence the behavior. If a child develops a dis-
order such as ADHD, and studies show that the biological
father but not the adopting father had ADHD, this is espe-
cially strong evidence of the role of genetic factors. This is
the conclusion reached from the ADHD adoption studies.
ADHD is a polygenic disorder
When diseases or disorders or traits are due to genetic fac-
tors, there are several mechanisms by which they can
inherited. Such conditions can essentially be divided into
single gene disorders and polygenic disorders. Single gene
disorders include hemophilia, cystic fibrosis, neurofi-
bromatosis and Huntington disease. In single gene disor-
ders a rare mutation results in the complete disruption of
the function of a gene. Some of the greatest advances in
genetics during the past 100 years have come from the elu-
cidation of the genes for virtually every single gene disor-
der. Their DNA has been cloned, sequenced and the gene
localized to a specific chromosomal region.
Polygenic disorders, by contrast, are due to the interactive
or epistatic effects of many different genes on different
chromosomes, each gene contributing to only a small part
of the picture (variance). These genes interact with envi-
ronmental factors. Except for a few rare families [12], all
behavioral disorders such as manic-depressive disorder,
schizophrenia, major depression, panic disorder, autism
and ADHD [3] are likely to be polygenic. While we do not
yet know the total number of genes involved, it is likely to
range from 50 to several hundred. In contrast to the gene
defects for single gene disorders (mutations), the defects
for polygenic disorders are much less severe, otherwise
they would be single gene disorders. Thus, we call them
gene variants instead of gene mutations, and individuals
have to inherit a number of them if they are to cause a
clinical effect [13]. A second distinction is that mutations
that severely affect gene function are very rare. Since they
are often present in less than 1 in 100,000 individuals the
diseases they cause are also very rare. In fact, all single
gene disorders combined affect less than 1.5% of the pop-
ulation. By contrast, the gene variants involved in poly-
genic disorders are common and polygenic disorders
themselves are common. This "common gene, common
disorder" theory of polygenic disorders has gained wide
acceptance. An alternative theory, of "rare gene, common
disorder," postulates a large number of rare mutations of
different genes [14].
In association studies of a wide range of behavioral disor-
ders, even when the association is significant the percent
of the variance attributable to that gene is usually in the
0.5 to 3% range and averages less than 1.5%. This suggests
that even if genes only account for 72 to 95% of the total
variance, 50 or more different genes would be involved
[15-17]. This does not mean that every affected individual
has inherited 50 or more of these variants. It is likely that
only a subset of the total potential set of gene variants is
required in a given individual. Because of this, polygenic
disorders show a great deal of genetic heterogeneity [17].
That is, different individuals with ADHD are likely to have
inherited somewhat different sets of genes. However, each
affected ADHD individual must have inherited enough
gene variants to pass a liability threshold, allowing them
to develop ADHD.
ADHD is a spectrum disorder
It has been known for many years that if an individual
inherits enough genes to develop any given behavioral
disorder, their risk of developing a second behavioral dis-
order is 2 to 4 times greater than for the general popula-
tion. This is probably because different behavioral
disorders share some gene variants. Thus, the more a per-
son exceeds the required threshold number of gene vari-
ants, the greater the likelihood they will develop more
than one behavioral problem, thus the term spectrum dis-
orders. Some of the most common coexisting or comor-
bid spectrum disorders seen in individuals with ADHD
are oppositional defiant disorder, conduct disorder,
major depressive disorder, anxiety disorders, obsessive
compulsive disorder, bipolar disorder, learning disorders,
and substance abuse disorder including alcoholism and
drug addiction. The frequency of some of these disordersTheoretical Biology and Medical Modelling 2005, 2:50 http://www.tbiomed.com/content/2/1/50
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is illustrated in Figure 1[4]. This shows the spectrum dis-
orders seen in the fathers of children with ADHD. Since
these fathers had not sought medical care, this type of
study avoids the biases inherent in a study of a clinic sam-
ple. The most likely explanation for the presence of spec-
trum disorders is that they share some genes in common,
as well as some genes unique to each disorder [15,16].
ADHD and many other complex disorders represent the 
upper end of a continuum of severity
After viewing the DSM-IV criteria for the diagnosis of
ADHD, one of the most commonly voiced objections is,
"every child has some of those symptoms." As with every
other polygenic trait, ADHD symptoms lie on a contin-
uum of severity. This is true of height, weight, IQ, blood
pressure, cholesterol level, depression, dyslexia, anxiety
and may other characteristics. These traits follow a bell-
shaped curve of magnitude or severity. Many children
have too few symptoms to meet the criteria. They may be
somewhat inattentive or hyperactive at times but they do
not meet all the criteria of ADHD. Note that 6 or more
symptoms must be present, must meet the qualifiers of
severity in the diagnostic criteria (almost everything is
"often" not "occasionally") they must be present for 6
months or more and must be maladaptive and inconsist-
ent with the normal developmental level. Because of these
qualifiers some individuals may barely meet the criteria
and are sufficiently mild not to require treatment. Others,
however, are at the extreme end of the bell-shaped curve
and are so symptomatic that everyone coming into even
brief contact with them can suspect the diagnosis. Physi-
cians arbitrarily pick a cut-off point for many diseases or
disorders. Those on the extreme end of the curve have the
disorder, those with less extreme symptoms do not. This
may give a false illusion of a dichotomous trait. For exam-
ple, the diagnosis of hypertension is usually based on a
consistent diastolic blood pressure of 90 mmHg or more.
Some individuals have severe life threatening hyperten-
sion with a diastolic blood pressure consistently above
120 mmHg while others have mild hypertension where
the diastolic blood pressure is sometimes normal and
sometimes too high. Because it is a continuum does not
mean hypertension does not exist.
An even better example is depression. Everyone is occa-
sionally depressed. This does not mean the diagnosis of
major depression is invalid or worthless because everyone
can relate to it. Some are so depressed they sleep all the
time, can't get out of bed, eat poorly, lose or gain weight,
have zero libido, are suicidal and desperately need treat-
Comorbid disorders in ADHD from Biederman et al, 1993 [82] Figure 1
Comorbid disorders in ADHD from Biederman et al, 1993 [82].
0 5 1 01 52 02 53 03 54 04 55 0
Percent
Oppositional Defiant Disorder
p < .001
p < .001 Conduct disorder
Antisocial personality disorder
p < .001
Major depressive disorder
p < .01
Alcohol dependence
p < .001
Multiple anxiety disorders
p < .001
Overanxious disorder p < .001
Generalized anxiety disorder p < .001
Social phobia
p < .01
Enuresis p < .01
ADHD fathers
ControlsTheoretical Biology and Medical Modelling 2005, 2:50 http://www.tbiomed.com/content/2/1/50
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ment. Ironically, even some professionals who clearly
understand that major depression is a real entity but lies
on a continuum of severity may have trouble understand-
ing that the same is true of ADHD. The cut-off point is set
to secure help for those with symptoms severe enough to
interfere with their lives, and leave those with minimal
symptoms with no diagnosis.
ADHD has lifelong effects
One of the most common misconceptions about ADHD
is that it goes away by the time an individual is a young
adult. In California, this is written into the MediCal law.
Stimulants are no longer covered for the treatment of
ADHD in adults because it is assumed the disorder is gone
by that time. One feature leading to this misconception is
that motor hyperactivity often does decrease with age.
However, there is much less decrease in inattention, and
if individuals are rated on a global assessment of function-
ing, there is little improvement with age [4].
Stimulus hypersensitivity and "overload."
While stimulus overload is especially characteristic of chil-
dren with autism, many children with ADHD are also very
sensitive to sound, sight, smell or other sensory inputs
[18]. Awareness of this helps parents and teachers to
understand poor attention in large, noisy school class-
rooms. Reports suggest that some ADHD children are
responding so intensely to environmental stimuli ignored
by other children that their experience is comparable to
trying to talk on a cell phone in a crowded, noisy bar-
room. As one teacher reported, for example, a boy diag-
nosed with ADHD told her, at the end of class on his first
day of Ritalin treatment: "It's wonderful: now I can hear
you."
Learning primarily with visual images
Two pathways relevant to learning are that linking the lin-
guistic cortex to the hippocampus and that for remember-
ing visual images, which links the visual cortex to the
hippocampus via the dorsolateral medial entorhinal cor-
tex [19]. The latter pathway is essential for spatial orienta-
tion and tracking, and spatial memory – as in how we
remember where our car is parked. Some ADHD children
have difficulty with this skill. Others have difficulties with
the linguistic memory pathway. This is typified by ADHD
children with comorbid dyslexia who are unable to make
images of written words that link the auditory linguistic
cortex to memory. They might, for example, have diffi-
culty distinguishing between the spelling "otehr" and
"other."
ADHD versus ADHD + conduct disorder
There have been a number of longitudinal studies of
ADHD in which a group of individuals diagnosed in
childhood were followed for a number of years to assess
how they performed as adults [20-23]. In many of these
Table 3: DSM-IV Criteria of Conduct Disorder
A. A repetitive and persistent pattern of behavior in which the basic rights of other or major age-appropriate societal norms or rule are violated, as 
manifested by the presence of three (or more) of the following criteria in the past 12 months, with at least one criterion present in the past 6 
months.
Aggression to people and animals
(1) often bullies, threatens, or intimidates others
(2) often initiates physical fights
(3) has used a weapon that can cause serious physical harm to others (e.g. a bat, brick, broken bottle, knife, gun)
(4) has been physically cruel to people
(5) has been physically cruel to animals
(6) has stolen while confronting a victim (e.g., mugging, purse snatching, extortion, armed robbery)
(7) has forced someone into sexual activity
Destruction of property
(8) has deliberately engaged in fire setting with the intention of causing serious damage
(9) has deliberately destroyed others' property (other than by fire setting)
Deceitfulness or theft
(10) has broken into someone else's house, building, or car
(11) often lies to obtain goods or favors or to avoid obligations (i.e., "cons" others)
(12) has stolen items of nontrivial value without confronting a victim (e.g., shoplifting, but without breaking and entering; forgery)
Serious violations of rules
(13) often stays out at night despite parental prohibitions, beginning before age 13 years
(14) has run away from home overnight at least once while living in parental or parental surrogate home (or once without returning for a lengthy 
period)
(15) is often truant from school, beginning before age 13 years
B. The disturbance in behavior causes clinically significant impairment in social, academic, or occupational functioning
C. If the individual is age 18 years or older, criteria are not met for Antisocial Personality Disorder
Specify type based on age at onset:
Childhood-Onset Type: onset of at least one criteria characteristic of Conduct Disorder prior to age 10 years
Adolescent-Onset Type: absence of any criteria characteristic of Conduct Disorder prior to age 10 years
Specify severity: mild (few criteria met), moderate and severe (many criteria met)Theoretical Biology and Medical Modelling 2005, 2:50 http://www.tbiomed.com/content/2/1/50
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studies the outcome was poor, with significant increases
in substance abuse, trouble with the law, difficult inter-
personal relationships and problems with employment.
This has given the impression that all ADHD children
have a bad outcome. However, when some of these stud-
ies were carefully analyzed, or when the study itself was
appropriately designed, it became apparent that if the
cases are divided into those with ADHD only and those
with ADHD + conduct disorder (CD), it was the ADHD +
CD cases that had poor outcomes while the ADHD only
individuals often had outcomes that were not markedly
different from those of normal children. This is consistent
with the many studies in the past 50 years that have
shown that one of the most stable of all diagnoses in psy-
chiatry is CD [24-27]. On average, 50% of children diag-
nosed as conduct disorder still had symptoms of CD, or its
adult equivalent, antisocial personality disorder (ASPD),
5 to 25 years later [24-28]. The DMS-IV-TR criteria for con-
duct disorder are given in Table 3. CD is present in 25 to
40% of ADHD children. Up to 25 percent of male prison
inmates have ADHD + ASPD [29]. Treatment of ADHD in
a prison population results in improved behavior and
lower recidivism rates if the treatment is continued after
release [30].
ADHD + ODD
A second disorder commonly comorbid with ADHD is
oppositional defiant disorder (ODD). The DMS-IV crite-
ria for ODD are given in Table 4. It is the ODD rather than
the ADHD symptoms that most often drive parents to dis-
traction. An interesting aspect of ODD is that it is often
site specific. Thus, many children only present with ODD
symptoms in the home, and often direct the behavior at
their mother. Some children with severe ODD at home
can be angels at school. It is likely that they control their
tantrums and talking back at school because peer pressure
prevents them from making fools of themselves in front of
others. They have no such restraint at home. ODD is
present in 40 to 60% of children with ADHD [31,32]. The
most credible explanation for why these two disorders,
and other comorbid disorders, are so common in ADHD
is that they share many genes in common [16].
ADHD has a lifelong effect on function
Having pointed out that much of the poor outcome in
ADHD children is due to the comorbid presence of CD,
we would like to present the 1985 study by Howell and
coworkers [22]. While this longitudinal study did not dis-
tinguish between ADHD and ADHD + CD, it did some-
thing no other study has done: it compared the outcomes
of three groups of children instead of just ADHD children
and controls. Children in the early grade school years were
evaluated on a continuum of ADHD symptoms and
divided into three groups, those scoring in the highest
10% (ADHD group), those in the lowest 10% (low ADHD
group), and the rest ("normal") group. They were then re-
evaluated after they graduated from high school. The
remarkable finding was that in virtually every aspect of life
the low ADHD group performed best, the normals were
intermediate and the ADHD group performed worst (Fig-
ure 2). This should not be taken to suggest that children
with ADHD always underachieve. Again, we wish to
emphasize there are many examples in which the restless,
workaholic, always-have-to-be-doing-something, I-need-
to-be-my-own-boss, characteristics of ADHD subjects
result in very successful lives. Thus, in the right combina-
tion, some of the symptoms we have been discussing in a
negative light can be used to great advantage.
ADHD is a disorder of prefrontal lobe function
Many of the symptoms of ADHD parallel the symptoms
of individuals with destructive lesions of the prefrontal
lobes [33-35]. When the dorsolateral portions of the pre-
frontal lobes are affected by traumatic injury there is
impaired attention, distractibility, disinhibition of behav-
ior, poor long term planning, impulsivity, lack of motiva-
tion, poor abstract reasoning, poor executive functioning
and poor organizational skills, all of which are present in
Table 4: DSM-IV Criteria of Oppositional Defiant Disorder
A. A pattern of negativistic, hostile, and defiant behavior lasting at least 6 months, during which four (or more) of the following are present:
(1) often loses temper
(2) often argues with adults
(3) often actively defies or refuses to comply with adult's requests or rules
(4) often deliberately annoys people
(5) often blames others for his or her mistakes or misbehavior
(6) is often touchy or easily annoyed by others
(7) is often angry and resentful
(8) is often spiteful or vindictive
Note: Consider a criterion met only if the behavior occurs more frequently than is typically observed in individuals of comparable age and 
developmental level.
B. The disturbance in behavior causes clinically significant impairment in social, academic, or occupational functioning.
C. The behaviors do not occur exclusively during the course of a Psychotic or Mood Disorder.
D. Criteria are not met for Conduct Disorder, and if the individual is aged18 years or older, criteria are not met for Antisocial Personality 
Disorder.Theoretical Biology and Medical Modelling 2005, 2:50 http://www.tbiomed.com/content/2/1/50
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ADHD individuals. By contrast, lesions of the orbitome-
dial portion of the frontal lobe are associated with aggres-
sion, emotional outbursts, poor self-control, lack of guilt,
empathy or remorse, and anti-social and psychopathic
behavior [36]. These are the symptoms typical of CD and
antisocial personality disorder. Thus, the finding that
ADHD is a genetic disorder suggests the defective genes
involved cause a dysfunction of the prefrontal lobes. As
discussed below, one of the brain neurotransmitters likely
to be involved in causing this dysfunction is dopamine.
Some ADHD is a disorder of parietal lobe function
In some children with ADHD, especially those with learn-
ing disorders, the parietal lobes are also likely to be
involved [37]. Studies of children with both ADHD and
reading or other learning disabilities indicated they had
abnormally high levels of norepinephrine breakdown
products [38]. Norepinephrine is the arousal neurotrans-
mitter of the brain, associated with waking the brain up in
the morning and setting it to an optimal level of arousal.
Studies in animals suggest that both too much and too lit-
tle norepinephrine can be associated with hyperactivity
[39]. The parietal lobes also carry some of the centers for
speech and language as well as an area for attention. Thus,
it is not surprising that defects in the parietal lobes can be
associated with ADHD combined with learning disorders.
ADHD and substance abuse
As mentioned above, two of the common comorbid spec-
trum disorders in ADHD are alcoholism and drug abuse
[4044]. The reward pathways of the brain are also located
in the frontal lobes and limbic system. They provide pleas-
ure for a number of behaviors that are critical to the con-
tinued existence of the individual and the species, such as
eating and having sex. These are termed natural rewards.
The reward pathways are rich in dopamine carrying neu-
rons and it is the release of dopamine that produces the
feelings of pleasure. In addition to food and sex, all drugs
of abuse result in the release of dopamine in the reward
pathways. This is responsible for the feelings of euphoria
or the high that these drugs produce. These are termed
unnatural rewards. We have previously proposed a
Reward Deficiency Syndrome (RDS) [45] suggesting that
genetic variants in dopamine genes result in defective
functioning of the reward system such that individuals
with these defects are much more likely to seek out addi-
tional stimulation of their reward pathways by turning to
drugs, alcohol, excessive sexual activity and risk-taking
activities such as hang gliding and bungie jumping. In this
regard, Lee et al. [46] found an association between nov-
elty seeking (NS) and both the dopamine D4 receptor
gene (DRD4) long alleles and the Taq1 A1 and Taq1 B1
sites of the dopamine D2 receptor gene. The term Taq1
refers to the type of restriction endonuclease that cuts a
DNA sequence at a specific site. These results therefore
confirmed previous findings in which the long repeats of
the DRD4 polymorphism were related to NS personality
trait, and suggested that the less frequent DRD2 alleles
were also associated with the reward -dependent trait [47].
ADHD and pathological gambling
Different neurological studies have found pathological
gamblers to have high impulsivity and poor performance
in tasks involving frontal/executive functions. These
symptoms are similarly observed with individuals diag-
nosed with ADHD. It is noteworthy that pathological
gambling is an addiction that is not confounded by the
problems of ingesting a drug. PET studies of individuals
engaged in video poker have documented a release of
dopamine in the striatum [48]. We found that 50.9 %of
171 pathological gamblers carried the D2A1 allele com-
pared to 25.9% of the 714 known non-Hispanic Cauca-
sian controls screened to exclude drug and alcohol abuse;
p <0.000001, odds ratio = 2.96 [49]. The DRD2 gene was
associated with severity in that the D2A1 allele was present
in 63.8% of those in the upper half of severity (odds ratio
versus controls = 5.03) compared to 40.9% in the lower
half of severity. Of those who had no comorbid substance
abuse, 44.1% carried the D2A1 allele, compared to 60.5%
Longitudinal studies of children with low, intermediate and  high ADHD scores in early grade school, from Howell et al:  Pediatrics 76:185–190, 1985 [22] Figure 2
Longitudinal studies of children with low, intermediate and 
high ADHD scores in early grade school, from Howell et al: 
Pediatrics 76:185–190, 1985 [22].
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of those who had comorbid substance abuse. These
results suggest that genetic variants at the DRD2 gene play
a role in pathological gambling and support the concept
that variants of this gene are a risk factor for impulsive and
addictive behaviors 49
In this regard, others have utilized questionnaires, struc-
tured interviews and behavioral tasks to evaluate the his-
tory of ADHD in pathological gamblers. It was found that
pathological gamblers scored higher on the Barratt Impul-
sivity Scale (BIS) than controls, but only those with a his-
tory of childhood ADHD showed a greater impulsivity in
behavioral tasks [50].
As discussed below, it has often been claimed that the
treatment of ADHD with stimulants will encourage chil-
dren to abuse drugs when they are older. It is much more
likely that ADHD and substance abuse share many gene
variants in common, and share a deficiency of dopamine
in the frontal lobe and limbic system, and this is the rea-
son ADHD and especially ADHD + CD children are also
at risk for substance abuse. The best way to prevent sub-
stance abuse is to ensure that the ADHD and the resulting
frontal and parietal lobe dysfunctions are adequately
treated so these individuals do not turn to street drugs to
self-medicate. Studies suggest that the prevalence of sub-
stance abuse disorder is lower in ADHD children who are
adequately treated with stimulants than in those who are
untreated [51].
What genes are involved?
It is one thing to know that a disorder is largely genetic
and another to know which genes are involved, especially
if the disorder is polygenically inherited. Because each
gene contributes to only a small part of the total picture,
the gene variants involved can be difficult to identify. The
most powerful method is the use of association studies.
These studies compare the frequency of gene variants
(polymorphisms) in individuals with and without
ADHD, or examine whether certain gene variants are pref-
erentially transmitted to a child with ADHD. The genes
that have been examined in ADHD and related behavioral
disorders tend to be in three classes: enzymes, receptors
and transporters, especially those that involve neurotrans-
mitters. Binding to the post-synaptic cell occurs at recep-
tors that are specific for a given transmitter. In addition to
being broken down by enzymes, the neurotransmitters
can be cleared from the synapse by transporters that
return the neurotransmitters to the pre-synaptic cell. As
with the receptors, the transporters are neurotransmitter-
specific. Perhaps the best known example is the serotonin
transporter. Drugs that inhibit the action of the serotonin
transporter are called selective serotonin re-uptake inhib-
itors or SSRIs.
There are an estimated 25,000 human genes. More effi-
cient methods for testing large numbers of genes in asso-
ciation studies are rapidly being developed. Until these
techniques are fully developed and relatively inexpensive,
we perforce examine the genes (candidate genes) that we
feel are most likely to be involved. To date, variations at a
number of candidate genes have shown a significant asso-
ciation with ADHD. These include genes for three
dopamine receptors (DRD2, DRD4, DRD5), the
dopamine transporter (DAT1 or SLC6A3), the serotonin
transporter (HTT or SLC6A4), norepinephrine receptors
(ADRA2A, ADRA2C), the norepinephrine transporter
(NET or SLC6A2), and others [15,16,52]. Of these, we will
only discuss the dopamine transporter in more detail
because it has relevance to ADHD in both humans and
animals, the association has been replicated in a number
of studies, and it has important implications for under-
standing the mechanism of action of the stimulants and
possibly for identifying which individuals are most likely
to respond to treatment.
The most frequently examined variant in the dopamine
transporter is a 40 base pair repeat polymorphism. The
most common variants or alleles are called 9 and 10. A
number of studies have shown that the 10 allele is more
common in Caucasians with ADHD. Brain imaging stud-
ies show an increased availability of the dopamine trans-
porter in ADHD subjects compared to controls across all
age groups [53]. It is especially interesting that these stud-
ies have also shown that the treatment of ADHD subjects
with methyphenidate (Ritalin) decreases the level of the
dopamine transporter availability back to normal or
below normal levels [54]. In contrast to the association of
ADHD in humans with elevated DAT1 levels, knockout
mice that have no DAT1 gene are also very hyperactive
[55]. While this may seem to contradict the human stud-
ies, a number of compensatory effects can occur when a
gene is totally eliminated at conception. In addition, both
too much and too little of a neurotransmitter may have
similar effects in many systems. Some preliminary studies
have suggested a differential response of methylphenidate
in those who carry different alleles of the DAT1 gene [56].
Furthermore, it has been suggested [56] that children pos-
sessing the 10 repeat VNTR allele of the DAT1 gene might
be particularly responsive to methylphenidate because of
its DAT-blocking action. Others have further examined
this hypothesis. In a sample of 119 Irish children, Killey et
al. [57] also reported that the 10 repeat allele predicted a
positive clinical outcome. Not all studies have found this
association, but it begins to open the way to predicting
drug response by genetic testing before the drugs are
given.
A number of genome scans, using sibling-pair linkage
techniques for identifying relevant genes, have been per-Theoretical Biology and Medical Modelling 2005, 2:50 http://www.tbiomed.com/content/2/1/50
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formed [58,59]. A number of chromosomal sites showing
significant but modest linkage have been identified. There
is agreement between studies about some areas and disa-
greement about others. Association studies will have to be
performed to identify the specific genes in the areas
responsible for the positive signals.
Because the DAT1 and other genes contribute to only a
modest part of the total picture, a more powerful method
of examining the genetics of ADHD may be to test the
interactive (epistatic) effects of multiple genes. Prelimi-
nary studies simultaneously examining variants at 42 dif-
ferent genes indicate the importance of norepinephrine
genes in the etiology of ADHD [16]. These studies, still in
their infancy, may point the way toward understanding
the complex genetics of ADHD and its comorbid condi-
tions, identifying genetic subtypes of ADHD, and identi-
fying before any drugs are given who will respond to
which drugs and who may have undesirable side effects.
Since there is some overlap with SUD in many ADHD
adults, the possible role of other dopaminergic genes and
regulators should not be overlooked [60-65].
Treatment of ADHD: Why use stimulants? How do they 
work?
Many double blind studies over the past 40 years have
agreed that stimulants such as methylphenidate, dextro-
amphetamine, and others are very effective in the treat-
ment of 70–80 % of children and adults with ADHD. One
of the myths of ADHD is that ADHD children show a par-
adoxical effect of being calmed by stimulants while "nor-
mal" individuals are stimulated by them. However,
studies have shown that activity levels are decreased and
attention levels are increased by stimulants in individuals
with and without ADHD. The difference is that since the
levels of hyperactivity and inattention are much higher in
ADHD subjects, the improvement is relatively much
greater, giving the impression that they respond while
non-ADHD subjects do not.
How do stimulants work? It is known that, as in the effect
of SSRIs on the serotonin transporters, the stimulants
inhibit dopamine transporters (and norepinephrine
transporters). Since hyperactivity is related to excessive
dopamine activity in the basal ganglia, this would seem
on the face of it to make things worse instead of better.
However, Figure 3 illustrates the stimulants work in
ADHD. Figure 3a shows the basal, unstimulated state with
dopamine stored in the vesicles and low levels of
dopamine in the synapse. Figure 3b shows the result of
stimulation of the dopamine neuron, with the vesicles
releasing dopamine into the synapse and re-uptake of the
dopamine into the presynaptic neuron by the dopamine
transporters. Figure 3c shows that in the presence of stim-
ulants, the function of the dopamine transporters is par-
tially blocked and the basal level of dopamine increases in
the synapse. This results in occupation of the presynaptic
dopamine D2 receptors. When the nerve is stimulated
(Figure 3d), the amount of dopamine released from the
vesicles is deceased because of the occupation of the pres-
ynaptic D2  receptors. This results in a decrease in
dopaminergic stimulation in the basal ganglia, where the
density of the D2 receptors is the highest. Of particular
interest, there are few D2 receptors in the prefrontal lobe.
Thus, dopamine activity in the prefrontal lobes is
increased instead of decreased. This is consistent with a
model of ADHD in which there is too little dopamine in
the frontal lobes, hence the symptoms of prefrontal lobe
deficits, and too much dopamine in the basal ganglia,
hence motor hyperactivity and, not infrequently, motor
tics [66]. The stimulants correct both the prefrontal lobe
deficiency and the basal ganglion excess of dopamine.
Despite this indication of how well-suited stimulant med-
ications are to the treatment of ADHD, many still worry
that our children are receiving a form of "speed." Studies
have shown that in order to obtain a "high", stimulants
need to reach the brain very quickly. This requires intrave-
nous or nasal administration, or the use of doses that
exceed therapeutic recommendations. At therapeutic oral
doses the stimulants used for treatment of ADHD do not
cause a euphoric high. Perhaps the best indicator of this is
that one of the hardest parts of the treatment of ADHD
children is to get them to take their medication; they do
not come begging for more. This, however, is no guaran-
tee that these drugs are never abused. It is important that
children and adolescents with ADHD should not have
free access to their medications, since it is clear that these
drugs can be abused when given nasally, or intravenously
or in high doses. Keeping track of the medications helps
to ensure that they are not sold for illicit use. There is also
the potential problem of inducing aggressive behavior in
those individuals possessing the DRD2 Taq A1 allele [67].
A second class of medications that work primarily on
norepinephrine pathways, such as clonidine, guanifacine,
and atomoxetine, can also be quite effective. Clonidine
and guanifacine are especially useful in treating individu-
als with both ADHD and chronic tics (Tourette syn-
drome) since clonidine and guanifacine uniquely treat
both these conditions [68]. Physicians are often reluctant
to treat individuals with ADHD and Tourette syndrome
with stimulants for fear of exacerbating the tics. However,
consistent with the above mechanism of action of stimu-
lants, significant exacerbation is unusual and often the tics
are unchanged or improved following stimulant treat-
ment [69].Theoretical Biology and Medical Modelling 2005, 2:50 http://www.tbiomed.com/content/2/1/50
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Treatment of ADHD comorbid disorders
As indicated above, it is often the comorbid disorders such
as ODD and CD that cause the greatest distress to parents
of children with ADHD. In our experience, the atypical
neuroleptics such as risperidone, olanzipine and molin-
done can be very effective in the treatment of these comor-
bid conditions.
Alternative treatments
Because of their concern about the use of medications,
many parents seek alternative methods of treatment of
ADHD. Most clinicians agree that a combination of med-
ication and behavioral modification is the most effective
approach to the treatment of ADHD, even though the
medications contribute the most [70]. Children with
ADHD may also respond well to adjustments in educa-
tion such as those provided by an Individual Education
Plan (IEP). The following additional alternatives are
among the most often used.
Family therapy and education
Family therapy relates to therapy that involves every mem-
ber of the family. This can be especially effective since
there are often many issues that affect the entire family.
These involve educating the parents, siblings and affected
child that ADHD is a genetic-biochemical disorder and is
Dexedrine mode of action Figure 3
Dexedrine mode of action. From Seeman and Madras: Mol. Psychiatry 3:386–396,1998 [83].
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not the child's fault. This does not mean that ADHD chil-
dren should not be held responsible for their behavior. It
does mean that the level of discipline needs to be modu-
lated by an understanding of the biological basis of the
disorder. Family therapy can also address the frequent
concern of siblings that the misbehaving child often gets
a disproportionate degree of attention. Many other issues
relating to having a child with ADHD in the family benefit
from family therapy and parent education.
EEG biofeedback
EEG biofeedback usually utilizes feedback from a game
played on a TV screen to attempt by training to alter the
levels of alpha, beta and delta waves in the brain. It has
the advantage that no drugs are used and it appears to be
effective in some cases [71]. The disadvantages are that it
can be expensive; satisfactory double-blind testing of its
effectiveness has been very difficult; and the effects may
not be long-lasting. However, others have found success
with EEG neurofeedback training for ADHD in a clinical
setting [71].
Herbal remedies
A large number of herbal remedies have been used by
ADHD patients. Sometimes they seem to be effective,
sometimes not, or their effectiveness may be short-lived.
Many parents turn to them because they are perceived as
"natural." However, to be effective they must contain an
active ingredient and the identity of this ingredient is usu-
ally not known. In addition, a wide range of other ingre-
dients may be present that are not necessary or may cause
undesirable side effects [72].
Neutriceuticals
In contrast to herbal remedies, the compositions of neu-
triceuticals are precisely known. They usually consist of
amino acids, vitamins, minerals and other known com-
pounds. Because they are closer to food substances than
drugs, they do not have such rigorous FDA restrictions as
drugs and can be purchased over the counter. Because a
number of amino acids have direct or indirect effects on
the levels of specific neurotransmitters, they have the
potential for helping to control some of the symptoms of
ADHD. Neutriceuticals have the advantage that double-
blind studies can be easily carried out. It is not unlikely
that some combinations of the above compounds, care-
fully tested in double-blind studies, may play a support-
ing role in controlling some of the symptoms of ADHD
[73-75].
Heavy metal toxicity: Role in autism and ADHD
The frequencies of both autism and ADHD have appeared
to increase in the last decade or more. There has been par-
ticular emphasis on the possibility that the presence of
mercury in vaccines might play a role in this increase.
These issues have been reviewed in detail by Kirby [76],
including the potential interaction between heavy metals
and specific polymorphisms that may increase an individ-
ual's susceptibility to toxins. Because of this concern, mer-
cury has now been removed from all vaccines in the
United States; it was removed from vaccines in Sweden
and Denmark after 1993. Despite this, the frequency of
autism has either remained high or continued to increase
[77]. This lack of association with mercury in vaccines is
consistent with twin studies that show a very high herita-
bility for autism, thus implying minimal influence from
environmental factors. Mercury in vaccines has also been
implicated in the etiology of ADHD. While data on the
effect of removal of mercury from vaccines on the inci-
dence of ADHD in Sweden and Denmark are not availa-
ble, the results for autism, and the high heritability of
ADHD, suggest that mercury poisoning is probably not a
major factor. A role of other heavy metals such as lead and
manganese has also been suggested. It is difficult entirely
to rule out a role of heavy metal poisoning in ADHD, and
further studies are indicated. One of the appeals of the
theory that exposure to toxic substances that are new to
the environment may cause autism and ADHD is that it
may explain the increased frequencies of these disorders.
This is based in part on the assumption that increases in
frequency could not be due to increases in the frequency
of ADHD genes because gene variants do not increase in
frequency rapidly. One of us has suggested a mechanism
by which these genes could have rapidly increased in fre-
quency. This idea proposes that two factors unique to the
latter part of the 20th century could have played such a
role. These are the availability of effective birth control in
the 1960s, and the dramatic increase in the percentage of
individuals attending college since the Second World War.
Individuals carrying genes for ADHD and learning disor-
ders are less likely to go on to college and post graduate
work and more likely to start a family in their early 20 s.
Individuals who do not carry these genes are more likely
to attend college and put off childbearing into their late
20 s or early 30 s. This would result in a more rapid
increase in the first set of genes. Whether this would be
sufficient to account for an increase in frequency of
ADHD and autism must await studies of the frequency of
a range of genes by birth cohort.
Future perspective of genetic research
At the 4th International meeting of the Attention Deficit
Hyperactivity Disorder Molecular Genetics Network,
chaired by Stephen V Farone, investigators from around
the world convened in May 2002 at Harvard Medical
School and presented their findings about genes and
ADHD. The putative ADHD genes with pooled odds
ratios greater than 1.0 included the following: DAT1 = 1.3;
DRD4 = 1.4; DRD5 = 1.5; and 5HT1B = 1.5. It was con-
cluded that although technological and statisticalTheoretical Biology and Medical Modelling 2005, 2:50 http://www.tbiomed.com/content/2/1/50
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advances in molecular genetics have allowed researchers
to begin to identify the association of specific genes with
ADHD, continued collaborative efforts are needed to elu-
cidate the genetic underpinnings of this complex pheno-
type fully [76]. Since this time, numerous other loci have
been shown to be associated with ADHD including cal-
cyon (DRD11P) [78], SNAP25, serotonin transporter,
dopamine β-hydroxylase, monamine oxidase A [79], tryp-
tophan hydroxylase 2 [80], TPH2 [80] several norepine-
phrine genes, BDNF, and others. Because of the small
percentage of the variance attributed to each gene, multi-
ple additional studies will be required to determine which
of these will be multiply replicated [81]. In the future, test-
ing for a panel of genes may lead to improved diagnosis
and treatment of ADHD.
Summary
ADHD is a common, complex, polygenic genetic, but
highly treatable disorder that can have a profound life-
long effect on brain function. The genes currently identi-
fied as playing a causative role in ADHD account for only
a small percentage of the total picture. The identification
of additional ADHD, CD and ODD genes, and their inter-
actions, holds the promise of firmly establishing ADHD
as a biological disorder and of identifying better methods
of diagnosis and treatment, emphasizing the need for
polypharmacy.
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